Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction

New England Journal of Medicine

Volumn 343, Issue 6, 2000, Pages 385-391

  Schömig, Albert ^a,b   Kastrati, Adnan ^a   Dirschinger, Josef ^a   Mehilli, Julinda ^a   Schricke, Ullrich ^a   Pache, Jürgen ^b   Martinoff, Stefan ^a   Neumann, Franz Josef ^b   Schwaiger, Markus ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR; HEPARIN; NITRIC ACID DERIVATIVE; TICLOPIDINE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; FEMALE; HEART REINFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; CEREBROVASCULAR ACCIDENT; COMBINED MODALITY THERAPY; FEMALE; FIBRINOLYTIC AGENTS; HEART; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIUM; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECURRENCE; STENTS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 0034632721     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200008103430602     Document Type: Article

References (38)

1. Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival: Should the paradigm be expanded?
2. Long-term effects of intravenous thrombolysis in acute myocardial infarction: Final report of the GISSI study
3. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2
4. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction
5. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction
6. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction
7. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction
8. Long-term outcome after primary angioplasty: Report from the Primary Angioplasty in Myocardial Infarction (PAMI-I) trial
9. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction
10. A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction
11. Clinical experience with primary percutaneous transluminal coronary angioplasty compared with alteplase (recombinant tissue-type plasminogen activator) in patients with acute myocardial infarction: A report from the Second National Registry of Myocardial Infarction (NRMI-2)
12. Acute myocardial infarction: Early diagnosis and management
13. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors
14. Coronary Palmaz-Schatz stent implantation in acute myocardial infarction
15. Coronary stent placement in patients with acute myocardial infarction: Comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy
16. Primary intracoronary stenting in acute myocardial infarction: Long-term clinical and angiographic follow-up and risk factor analysis
17. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction
18. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction
19. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade
20. Highlights from the American Heart Association 72nd Scientific Sessions: November 6 to 10, 1999
21. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents
22. Reproducibility of polar map generation and assessment of defect severity and extent assessment in myocardial perfusion imaging using positron emission tomography
23. Feasibility of tomographic 99mTc-hexakis-2-methoxy-2-methylpropyl-isonitrile imaging for the assessment of myocardial area at risk and the effect of treatment in acute myocardial infarction
24. Quantitative myocardial SPECT for infarct sizing: Feasibility of a multicenter trial evaluated using a cardiac phantom
25. Myocardial kinetics of technetium-99m-hexakis-2-methoxy-2-methylpropyl-isonitrile
26. Quantification of area at risk during coronary occlusion and degree of myocardial salvage after reperfusion with technetium-99m methoxyisobutyl isonitrile
27. Infarct size measured by single photon emission computed tomographic imaging with (99m)Tc-sestamibi: A measure of the efficacy of therapy in acute myocardial infarction
28. Myocardium at risk and infarct size after thrombolytic therapy for acute myocardial infarction: Implications for the design of randomized trials of acute intervention
29. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
30. A comparison of reteplase with alteplase for acute myocardial infarction
31. A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction
32. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomised trial
33. Coronary angioplasty with or without stent implantation for acute myocardial infarction
34. Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction
35. Prospective identification of myocardial stunning using technetium-99m sestamibi-based measurements of infarct size
36. Recognition of the importance of embolization in atherosclerotic vascular disease
37. Abciximab facilitates the rate and extent of thrombolysis: Results of the Thrombolysis in Myocardial Infarcfion (TIMI) 14 trial